Table 1.

Overview of Biologicals Approved or Tested for Atopic Dermatitis Treatment.

Biological	Target	Current phase of clinical trials	Main findings in clinical trials
Dupilumab	IL-4/IL-13	Approved for clinical use by EMA	EASI-75 improvement after 16-weeks of trial (Phase III) [11]
Tralokinumab	IL-13	Approved for clinical use by EMA	EASI-75 improvement & IGA 0 or 1 after 16-weeks of trial compared to placebo (Phase III) [19]
Lebrikizumab	IL-13	3, still recruiting	Up to 72.1% improvement EASI (250mg dose) after 16-weeks of trial compared to placebo (Phase IIb) [20]
Nemolizumab	IL-31	3, still recruiting	Up to 63.1% change in the pruritus VAS score after 12-weeks compared to placebo (Phase IIb) [24]
GBR830/IBS830	OX40	2b, finished, results not published	EASI-50 improvement after 71 days compared to placebo (Phase IIa) [26]
KHK4083	OX40	2a, completed, results not published	Continued improvement in EASI and IGA (Phase I) [27]
Tepezelumab	TSLP	2b, still recruiting	Numerical EASI50 improvement after 12-weeks of trial compared to placebo (Phase IIa) [28]
Etokimab	IL-31	2b, still recruiting	83% improvement of EASI50 and 33% EASI75 after 29-days of a single dose (Phase IIa) [33]
Fezakinumab	IL-22	2a, completed	SCORAD improvement greater compared to placebo at 12-weeks of trial (Phase IIa) [36]

^*Data from clinicaltrials.gov, Worm et al [18], & Li et al [17].